iX Biopharma Receivables

The latest receivables for 42C.SI is $2M as of June 2026. That compares with $1.9M in the prior-year period — up 1.7% year over year. Investors often review this figure alongside iX Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, 42C.SI's receivables moved from $1.9M to $2M — a 1.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in iX Biopharma's operating scale or balance-sheet position.

A receivables figure of $2M for 42C.SI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 42C.SI's receivables ($2M), review year-over-year change from $1.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.